Clinical Trials
4
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
A Multicentre Observational Study to Assess Long-term Outcome of Participants in the EXCELLENT Clinical Trial
- Conditions
- Acute Myocardial Infarction
- First Posted Date
- 2024-07-25
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- CellProthera
- Target Recruit Count
- 48
- Registration Number
- NCT06521047
- Locations
- 🇫🇷
CHU DIJON Hôpital François Mitterrand 14 rue Gaffarel, Dijon, France
🇫🇷Institut Jacques Cartier, Massy, France
🇫🇷CHU Montpellier Arnaud-De-Villeneuve, Montpellier, France
Donation of Whole Blood by Healthy Volunteers After Mobilisation by Haematopoietic Growth Factor (Rhu-G-CSF = Granocyte)
- First Posted Date
- 2022-10-26
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- CellProthera
- Target Recruit Count
- 40
- Registration Number
- NCT05594433
- Locations
- 🇫🇷
GHU La Pitié-Salpêtrière, Paris, France
🇫🇷CHRU Strasbourg, Strasbourg, France
SINGaporean Program Performed With an eXPANsion Medical Device (SingXpand)
- Conditions
- Heart Attack
- First Posted Date
- 2019-12-13
- Last Posted Date
- 2022-06-10
- Lead Sponsor
- CellProthera
- Registration Number
- NCT04198883
- Locations
- 🇸🇬
NHCS, Singapore, Singapore
EXCELLENT (EXpanded CELL ENdocardiac Transplantation)
- Conditions
- Acute Myocardial Infarction
- Interventions
- Drug: Standard Treatment for CHF post AMI
- First Posted Date
- 2016-02-01
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- CellProthera
- Target Recruit Count
- 49
- Registration Number
- NCT02669810
- Locations
- 🇫🇷
CHU BESANCON Hopital Jean Minjoz 3 Boulevard A.Fleming, Besançon, France
🇫🇷CHU DIJON Hôpital François Mitterrand 14 rue Gaffarel, Dijon, France
🇫🇷CHU de Grenoble, Grenoble, France
News
CellProthera Partners with CELLforCURE by SEQENS for Phase 3 Manufacturing of Heart Attack Cell Therapy
CellProthera has selected CELLforCURE by SEQENS as its CDMO partner for Phase 3 manufacturing of ProtheraCytes, an autologous expanded CD34+ stem cell therapy for severe heart attack patients.
CellProthera Initiates Long-Term Study of ProtheraCytes for Acute Myocardial Infarction
CellProthera has begun the PERFECT study, a 10-year observational follow-up to assess ProtheraCytes' long-term safety and efficacy after acute myocardial infarction.
CellProthera Advances ProtheraCytes Cell Therapy Program for Myocardial Infarction with FDA Alignment on Phase III Trial Design
CellProthera has secured FDA alignment on the design for a pivotal Phase III trial of ProtheraCytes, a cell therapy for acute myocardial infarction (AMI).